<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Expert guideline-based definitions of intermediate-risk prostate cancer and recommendations for active surveillance</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Expert guideline-based definitions of intermediate-risk prostate cancer and recommendations for active surveillance</h1>
<div class="graphic"><div class="figure"><div class="ttl">Expert guideline-based definitions of intermediate-risk prostate cancer and recommendations for active surveillance</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Guidelines</td> <td class="subtitle1" colspan="4">Intermediate-risk criteria</td> <td class="subtitle1" colspan="2">Active surveillance recommendations</td> </tr> <tr> <td class="subtitle2">PSA (ng/mL)</td> <td class="subtitle2">Pathology</td> <td class="subtitle2">Clinical stage</td> <td class="subtitle2">Favorable intermediate-risk</td> <td class="subtitle2">Candidates for surveillance</td> <td class="subtitle2">Surveillance protocol</td> </tr> <tr> <td>2018 <span style="white-space: nowrap;">ASCO<sup>[1]</sup></span></td> <td>10-20</td> <td><strong>-or-</strong> Gleason score 7</td> <td><strong>-or-</strong> cT2b</td> <td>Endorses AUA/ASTRO/SUO guidelines</td> <td>'Select' favorable intermediate-risk patients, including select patients with low volume, intermediate-risk (grade group 2) localized prostate cancer</td> <td>PSA every 3 to 6 months, yearly DRE, confirmatory TRUS biopsy within 6 to 12 months and every 2 to 5 years thereafter or more frequently if clinically indicated with consideration of MRI and genomic testing</td> </tr> <tr class="highlight_lght_gray_text"> <td>2021 EAU/EANM/ESTRO/ESUR/<span style="white-space: nowrap;">SIOG<sup>[2]</sup></span></td> <td>10-20</td> <td><strong>-or-</strong> Grade group 2 or 3</td> <td><strong>-or-</strong> cT2b</td> <td>Not specified</td> <td>'Highly selected' intermediate-risk patients with &lt;10% pattern 4</td> <td>No schedule specified</td> </tr> <tr> <td>2022 NCCN <span style="white-space: nowrap;">(v 1.2022)<sup>[3]</sup></span></td> <td>10-20</td> <td><strong>-or-</strong> Grade group 2 or 3</td> <td><strong>-or-</strong> cT2b/2c</td> <td>No more than single intermediate-risk factor, grade group 1 or 2, <strong>and</strong> &lt;50% positive biopsy cores</td> <td>Favorable intermediate-risk patients</td> <td>PSA no more than every 6 months and DRE, repeat biopsy, and repeat MRI no more than every 12 months unless clinically indicated</td> </tr> <tr class="highlight_lght_gray_text"> <td>2022 AUA/ASTRO<span style="white-space: nowrap;"><sup>[4,5]</sup></span></td> <td>10-20</td> <td><strong>-or-</strong> Grade group 2-3</td> <td><strong>-or-</strong> cT2b-c</td> <td>PSA 10-&lt;20 ng/mL and grade group 1, <strong>or</strong> clinical stage T2b-c and &lt;50% biopsy cores positive <strong>or</strong> PSA &lt;10 ng/mL with grade group 2 and clinical stage T1-2a and &lt;50% biopsy cores positive</td> <td>Favorable intermediate-risk patients</td> <td>No specified surveillance intervals but PSA no more frequently than every 6 months and individualized monitoring regimen based upon estimated risk of recurrence.</td> </tr> </tbody></table></div><div class="graphic_footnotes">PSA: prostate-specific antigen; ASCO: American Society of Clinical Oncology; AUA: American Urological Association; ASTRO: American Society for Radiation Oncology; SUO: Society of Urologic Oncology; DRE: digital rectal examination; TRUS: transrectal ultrasound; MRI: magnetic resonance imaging; EAU: European Association of Urology; EANM: European Association of Nuclear Medicine; ESTRO: European Society Radiation Oncology; ESUR: European Society of Urogenital Radiology; SIOG: Society of Geriatric Oncology; NCCN: National Comprehensive Cancer Network.</div><div class="graphic_reference">References:
<ol>
<li>Bekelman JE, Rumble RB, Chen RC, et al. Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 2018; 36:3251.</li>
<li>Mottet N, van den Bergh R CN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021; 79:243.</li>
<li>NCCN Clinical Practice Guidelines in Oncology: Version 1.2022. Available at: <a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp" target="_blank">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp</a> (Accessed September 29, 2021).</li>
<li>Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO Guideline, Part I: Introduction, risk assessment, staging, and risk-based management. J Urol 2022; 208:10.</li>
<li>Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO Guideline, Part II: Principles of active surveillance, principles of surgery, and follow-up. J Urol 2022; 208:19.</li>
</ol>
<p class="extra_spacing_top">Adapted and updated from: Overland MR, Washington SL 3rd, Carroll PR, et al. Active surveillance for intermediate-risk prostate cancer: yes, but for whom? Curr Opin Urol 2019; 29:605.</p></div><div id="graphicVersion">Graphic 130140 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
